The additive effects of Pranlukast in stable asthmatic patients with the regular use of FP/LABA combination drug (2) Open-label, randomized, and cross-over study

The additive effects of Pranlukast in stable asthmatic patients with the regular use of FP/LABA combination drug (2) Open-label, randomized, and cross-over study - The additive effects of Pranlukast in stable asthmatic patients with the regular use of FP/LABA combination drug (2) Open-label, randomized, and cross-over study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001007

Enrollment

Registered

2008-02-04

Start date

2008-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

The first 4 weeks are treated with FP/LABA combination drug and Pranlukast. The second 4 weeks are treated with only FP/LABA combination drug. The first 4 weeks are treated with only FP/LABA combinat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with FP/LABA combination drug more than 3 months. 2.Stable asthmatic patients who evaluate themselves to be well-controlled or better.

Exclusion criteria

Exclusion criteria: 1.Past treatments with anti-LT drugs in the previous 3 months. 2.Past treatments with oral corticosteroids in the previous 2 weeks. 3.Chronic obstructive lung disease(COPD) and other respitatory disease. 4.Severe liver, kidney, heart , hematic and other diseases 5.Inappropriate patients from the doctor's viewpoint.

Design outcomes

Primary

Measure	Time frame
Peripheral airway inflammation in induced sputum (Eosinophils, ECP and Eotaxin)	—

Secondary

Measure	Time frame
1.Asthmatic symptoms and QOL(AQLQ) 2.Pulmonary functions (PEF, FEV1, FEF50, FEF75) 3.Eosinophils in peripheral blood	—

Countries

Japan

Contacts

Public ContactHiroyuki Ohbayashi

JA Tohno Kousei Hospital Allergy and Respiratory Medicine

ohbayasi@nn.iij4u.or.jp0572-68-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026